Exelixis | Zinsaufwendungen Für Schuld



Interest Expense On Debt Veränderung Datum
Agios Pharmaceuticals 3.01M 10.05M 2024-12
Amgen USD 747M 29M 2024-12
AstraZeneca 429M 28M 2024-12
Bayer 703M 61M 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Bristol-Myers Squibb USD 496M 9M 2024-12
Cytokinetics USD 22.59M 296K 2024-12
Eisai 777M 167M 2024-12
Eli Lilly USD 224.7M 78.4M 2024-12
Exelixis 23.4M 3.9M 2023-09
Genmab DKK 2.68B 1.98B 2024-12
Glaxosmithkline 178.05M 24.73M 2024-12
Incyte USD 419K 355K 2024-12
Ionis Pharmaceuticals USD 2.59M 70K 2024-12
MacroGenics USD 0 6K 2024-09
Merck USD 328M 2M 2024-12
Moderna USD 6M 0 2024-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 275M 11M 2024-12
Pfizer USD 739M 45M 2024-12
Sanofi 66.11M 20.67M 2024-12
Takeda 31.6B 36.86B 2024-12
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Xencor -39359000 40.15M 2024-12



Exelixis Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.